peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma
Financial documents

Analysts and consensus

Analyst Coverage

BankAnalystEmailPhoneLocation
SEBChristopher Uhdechristopher.uhde@seb.se+46 876 385 53Stockholm
ABG Sundal CollierGonzalo Artiach CastañónGonzalo.Artiach@abgsc.se+46 73 321 73 96  Stockholm
RedeyeJohan Unnerusjohan.unnerus@redeye.se+46 724 023 385Stockholm
Van Lanschot KempenSuzanne van Voorthuizen

s.vanvoorthuizen@vanlanschotkempen.com

+31 6 29 71 3490

Amsterdam
CarnegieErik Hultgårderik.hultgard@carnegie.se+46 (0)8 5886 9237Stockholm
Intron Health ResearchNaresh ChouhanNaresh@IntronHealthResearch.com+44 7939 224 322London
Ökonomisk UgebrevLars Hatholthatholt@outlook.com+45 22 23 78 15Copenhagen
H.C. Wainwright & Co.Douglas Tsaodtsao@hcwresearch.com+1 212 916 3968New York City
William BlairMatt Phippsmphipps@williamblair.com+1 312 364 8602Chicago
Bryan, Garnier & Co.Alex Cogutacogut@bryangarnier.com+31 651 310 426Paris

Analyst Consensus

Updated 27-12-2023

   Patient uptake, EUProduct Sales estimates, SEKmRevenue estimates, SEKmEBIT, SEKmOperating Cash Flow, SEKmCash position, SEKm
Consensus modelPrice target, SEKWACCQ4'23eFY'23eFY'24eFY'25eQ4'23eFY'23eFY'24eFY'25eQ4'23eFY'23eFY'24eFY'25eQ4'23eFY'23eFY'24eFY'25eQ4'23eFY'23eFY'24eFY'25eQ4'23eFY'23eFY'24eFY'25e
Average8012%143874124349718330344134229381-174-772-630-508-146-783-651-538784720375179
Median9013%123765106329317526939126214313-177-784-650-575-146-774-720-610784716370295
High 17314%27481162556112129578575171371928-111-682-46241-99-664-412-66851894850547
Low168%8295985238313015632115130254-205-815-749-747-192-931-828-756716562-62-837
Number of contributions995777910101071010107109929992987
Recommendation
Buy 8
Hold 1
Sell 1

This is a company-collected consensus prepared with consolidated estimates submitted from research analysts covering the Hansa Biopharma stock. The consensus provided is based on a collection of estimates done on a quarterly basis. Any opinions, forecasts, estimates, projections or predictions regarding Hansa Biopharma’s performance made by the analysts (and, therefore, the consensus estimate numbers) are theirs alone and do not represent the opinions, forecasts, estimates, projections or predictions of Hansa Biopharma or its management. Hansa Biopharma does not by providing these estimates imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations made or provided by such analysts. Hansa Biopharma assumes no liability for the accuracy of such estimates and undertakes no obligation to update or revise such estimates.